NYSE:PKI

PerkinElmer - PKI Stock Forecast, Price & News

$133.26

+2.26 (+1.73%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $130.96
▼
$133.60
50-Day Range: $120.16
▼
$144.38
52-Week Range: $113.46
▼
$181.65

Volume: 624,610 shs
Average Volume: 872,078 shs
Market Capitalization: $16.85 billion

P/E Ratio: 29.10
Dividend Yield: 0.21%
Price Target: $166.30

Institutional Ownership

PerkinElmer MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 24.8% Upside
$166.30 Price Target
Short Interest: Healthy
2.59% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.99
Upright™ Environmental Score
News Sentiment: 0.65
Based on 7 Articles This Week
Insider Trading: Selling Shares
$1.37 M Sold Last Quarter
Proj. Earnings Growth: 17.79%
From $5.06 to $5.96 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.13 out of 5 stars

Computer And Technology Sector

13th out of 618 stocks

Analytical Instruments Industry

1st out of 29 stocks

2.3

Analyst's Opinion

Consensus Rating
PerkinElmer has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $166.30, PerkinElmer has a forecasted upside of 24.8% from its current price of $133.26.
Amount of Analyst Coverage
PerkinElmer has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.59% of the outstanding shares of PerkinElmer have been sold short.
Short Interest Ratio / Days to Cover
PerkinElmer has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PerkinElmer has recently decreased by 5.75%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
PerkinElmer has a dividend yield of 0.22%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
PerkinElmer does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of PerkinElmer is 6.11%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, PerkinElmer will have a dividend payout ratio of 4.70% next year. This indicates that PerkinElmer will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
PerkinElmer has received a 40.52% net impact score from Upright. PerkinElmer seems to create the most significant positive value in categories "Taxes", "Jobs", and "Creating knowledge". The positive contribution in the "Creating knowledge" impact category is mostly driven by its "Clinical research services", "Laboratory reagents", and "Centrifuges" products. See details.
Environmental Sustainability
The Environmental Impact score for PerkinElmer is -1.99.

3.1

News and Social Media Coverage

News Sentiment
PerkinElmer has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for PerkinElmer this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for PKI on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
6 people have added PerkinElmer to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PerkinElmer insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,370,737.00 in company stock.
Percentage Held by Insiders
Only 0.52% of the stock of PerkinElmer is held by insiders.
Percentage Held by Institutions
85.22% of the stock of PerkinElmer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for PerkinElmer are expected to grow by 17.79% in the coming year, from $5.06 to $5.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PerkinElmer is 29.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.01.
Price to Earnings Ratio vs. Sector
The P/E ratio of PerkinElmer is 29.10, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 349.37.
Price to Earnings Growth Ratio
PerkinElmer has a PEG Ratio of 0.55. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
PerkinElmer has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PerkinElmer (NYSE:PKI) Stock

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

March 25, 2023 | americanbankingnews.com

PerkinElmer, Inc. (NYSE:PKI) Insider Sells $1,328,876.52 in Stock

March 21, 2023 | americanbankingnews.com

PerkinElmer, Inc. (NYSE:PKI) Receives Average Recommendation of "Hold" from Analysts

April 1, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

March 13, 2023 | finance.yahoo.com

PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses

March 13, 2023 | finance.yahoo.com

Parkland Corporation Announces First Quarter 2023 Dividend

March 11, 2023 | finance.yahoo.com

Declining Stock and Decent Financials: Is The Market Wrong About PerkinElmer, Inc. (NYSE:PKI)?

March 9, 2023 | finance.yahoo.com

PerkinElmer to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

February 15, 2023 | finance.yahoo.com

PerkinElmer, Inc. (NYSE:PKI) Q4 2022 Earnings Call Transcript

April 1, 2023 | Weiss Ratings (Ad)

Urgent Warning

February 14, 2023 | finance.yahoo.com

PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022

January 24, 2023 | marketwatch.com

PerkinElmer Inc. stock falls Tuesday, underperforms market

January 24, 2023 | msn.com

The Latest Analyst Ratings for PerkinElmer

January 9, 2023 | finance.yahoo.com

PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook

December 26, 2022 | finance.yahoo.com

Investing in PerkinElmer (NYSE:PKI) five years ago would have delivered you a 95% gain

December 12, 2022 | finance.yahoo.com

PerkinElmer, Inc. (NYSE:PKI) is a favorite amongst institutional investors who own 82%

December 8, 2022 | finance.yahoo.com

Why Is PerkinElmer (PKI) Up 10.3% Since Last Earnings Report?

November 21, 2022 | finance.yahoo.com

PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays

November 17, 2022 | finance.yahoo.com

PerkinElmer Third Quarter 2022 Earnings: EPS Misses Expectations

November 16, 2022 | finance.yahoo.com

PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health

November 16, 2022 | seekingalpha.com

Could PerkinElmer Be The Next Danaher?

November 14, 2022 | finance.yahoo.com

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

November 10, 2022 | finance.yahoo.com

PerkinElmer to Present at 2022 Stifel Healthcare Conference

November 8, 2022 | finance.yahoo.com

PerkinElmer Announces Financial Results for the Third Quarter of 2022

November 8, 2022 | finance.yahoo.com

PerkinElmer (PKI) Q3 Earnings Surpass Estimates

October 19, 2022 | businesswire.com

Medical Device Innovation Consortium (MDIC) Partners with PerkinElmer's Horizon Discovery to Improve Accuracy of Next Generation Sequencing-Based Cancer Diagnostics - Business Wire

October 17, 2022 | finance.yahoo.com

PerkinElmer Sweetens Its Outlook And Shares Surge, But There's Still One Hitch

October 17, 2022 | marketwatch.com

PerkinElmer Sees 3Q Adj Earnings Topping Guidance - MarketWatch

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Ex-Dividend for 2/10 Dividend: 1/19/2023
Dividend Payable: 2/10/2023
Last Earnings: 2/14/2023
Today: 3/31/2023
Ex-Dividend for 5/12 Dividend: 4/20/2023
Next Earnings (Estimated): 5/02/2023
Dividend Payable: 5/12/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Sector: Computer and Technology
Current Symbol: NYSE:PKI
CUSIP: 71404610
CIK: 31791
Web: www.perkinelmer.com
Phone: (781) 663-6900
Fax: 781-663-5985
Employees: 16,700
Year Founded: 1937

Price Target and Rating

Average Stock Price Forecast: $166.30
High Stock Price Forecast: $182.00
Low Stock Price Forecast: $140.00
Forecasted Upside/Downside: +24.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.58
Trailing P/E Ratio: 29.10
Forward P/E Ratio: 26.34
P/E Growth: 0.55
Net Income: $569.18 million
Net Margins: 14.69%
Pretax Margin: 19.68%
Return on Equity: 13.94%
Return on Assets: 7.05%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 2.13
Quick Ratio: 1.87

Sales & Book Value

Annual Sales: $3.31 billion
Price / Sales: 5.09
Cash Flow: $12.23 per share
Price / Cash Flow: 10.90
Book Value: $58.49 per share
Price / Book: 2.28

Miscellaneous

Outstanding Shares: 126,410,000
Free Float: 125,755,000
Market Cap: $16.85 billion
Optionable: Optionable
Beta: 1.10

Social Links

Key Executives

Prahlad Ramadhar Singh
President, Chief Executive Officer & Director

Tajinder S. Vohra
Senior Vice President-Global Operations

Maxwell Krakowiak
Chief Financial Officer & Senior Vice President

Andrew Okun
Chief Accounting Officer, Treasurer & VP

Bryan A. Kipp
VP & General Manager-Life Sciences Integration

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PKI Stock - Frequently Asked Questions

Should I buy or sell PerkinElmer stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PKI shares.
View PKI analyst ratings or view top-rated stocks.
What is PerkinElmer's stock price forecast for 2023?: 10 brokerages have issued 1-year price objectives for PerkinElmer's stock. Their PKI share price forecasts range from $140.00 to $182.00. On average, they anticipate the company's share price to reach $166.30 in the next year. This suggests a possible upside of 24.8% from the stock's current price.
View analysts price targets for PKI or view top-rated stocks among Wall Street analysts.
How have PKI shares performed in 2023?: PerkinElmer's stock was trading at $140.22 at the beginning of 2023. Since then, PKI stock has decreased by 5.0% and is now trading at $133.26.
View the best growth stocks for 2023 here.
When is PerkinElmer's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our PKI earnings forecast.
How were PerkinElmer's earnings last quarter?: PerkinElmer, Inc. (NYSE:PKI) issued its quarterly earnings results on Tuesday, February, 14th. The medical research company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.66 by $0.04. The medical research company had revenue of $741.20 million for the quarter, compared to the consensus estimate of $1.07 billion. PerkinElmer had a net margin of 14.69% and a trailing twelve-month return on equity of 13.94%. The firm's revenue for the quarter was down 27.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.56 earnings per share.
How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?: PerkinElmer announced a quarterly dividend on Thursday, January 26th. Stockholders of record on Friday, April 21st will be given a dividend of $0.07 per share on Friday, May 12th. This represents a $0.28 annualized dividend and a yield of 0.21%. The ex-dividend date of this dividend is Thursday, April 20th.
Read our dividend analysis for PKI.
What ETFs hold PerkinElmer's stock?: ETFs with the largest weight of PerkinElmer (NYSE:PKI) stock in their portfolio include AXS Cannabis ETF (THCX), First Trust Indxx Medical Devices ETF (MDEV), WisdomTree BioRevolution Fund (WDNA), Franklin Genomic Advancements ETF (HELX), Janus Henderson US Sustainable Equity ETF (SSPX), Invesco S&P 500 Equal Weight Health Care ETF (RYH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Guru Index ETF (GURU).
Is PerkinElmer a good dividend stock?: PerkinElmer (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.22%. The dividend payout ratio is 6.11%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.70% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.
What guidance has PerkinElmer issued on next quarter's earnings?: PerkinElmer issued an update on its FY23 earnings guidance on Tuesday, February, 14th. The company provided earnings per share guidance of $5.05 for the period, compared to the consensus EPS estimate of $5.67. The company issued revenue guidance of $2.94 billion, compared to the consensus revenue estimate of $3.12 billion.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?: 27 employees have rated PerkinElmer Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.
What other stocks do shareholders of PerkinElmer own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).
What is PerkinElmer's stock symbol?: PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."
Who are PerkinElmer's major shareholders?: PerkinElmer's stock is owned by a variety of retail and institutional investors. Top institutional investors include Moneta Group Investment Advisors LLC (9.41%), Select Equity Group L.P. (7.75%), T. Rowe Price Investment Management Inc. (7.45%), Geode Capital Management LLC (2.01%), Price T Rowe Associates Inc. MD (1.75%) and Alliancebernstein L.P. (1.12%). Insiders that own company stock include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Maxwell Krakowiak, Peter Barrett, Prahlad R Singh, Sylvie Gregoire and Tajinder S Vohra.
View institutional ownership trends.
How do I buy shares of PerkinElmer?: Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PerkinElmer's stock price today?: One share of PKI stock can currently be purchased for approximately $133.26.
How much money does PerkinElmer make?: PerkinElmer (NYSE:PKI) has a market capitalization of $16.85 billion and generates $3.31 billion in revenue each year. The medical research company earns $569.18 million in net income (profit) each year or $4.58 on an earnings per share basis.
How many employees does PerkinElmer have?: The company employs 16,700 workers across the globe.
Does PerkinElmer have any subsidiaries?: The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More
How can I contact PerkinElmer?: PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 4/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PerkinElmer - PKI Stock Forecast, Price & News

PerkinElmer MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About PerkinElmer (NYSE:PKI) Stock

PKI Stock News Headlines

PKI Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PKI Stock - Frequently Asked Questions

Overall MarketRank^™